PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21092078-9	2010	Low nanomolar concentrations of flavopiridol induced G2 arrest, which was correlated to down-modulation of cyclin B1 and up-regulation of p53.	alvocidib	32-44	cyclin B1	Homo sapiens	107-116	
16731754-4	2006	Treatment of DU 145 prostate cancer cells with 500 nmol/L flavopiridol and 10 nmol/L docetaxel inhibited apoptosis probably because of their opposing effects on cyclin B1-dependent kinase activity.	alvocidib	58-70	cyclin B1	Homo sapiens	161-170	
20206141-6	2010	The addition of flavopiridol following PBOX-6 treatment did however result in an accelerated exit from the G2/M transition accompanied by an enhanced downregulation and deactivation of the CDK1/cyclin B1 complex and an enhanced degradation of the inhibitor of apoptosis protein (IAP) survivin.	alvocidib	16-28	cyclin B1	Homo sapiens	194-203	
16731754-11	2006	Overall, our data suggest that the docetaxel and flavopiridol combination requires a maximal effect on cyclin B1-dependent kinase activity and a reduction of XIAP and AKT prosurvival proteins for augmentation of apoptosis in LNCaP cells.	alvocidib	49-61	cyclin B1	Homo sapiens	103-112	
12813134-9	2003	Flavopiridol treatment of docetaxel-treated cells enhances the exit from mitosis with a more rapid decrease in mitotic markers including MPM-2 labeling and cyclin B1/cdc2 kinase activity.	alvocidib	0-12	cyclin B1	Homo sapiens	156-165	
12813134-10	2003	In contrast, pretreatment with flavopiridol prevents cells from entering mitosis by inhibiting cyclin B1/cdc-2 kinase activity, thus antagonizing the docetaxel effect.	alvocidib	31-43	cyclin B1	Homo sapiens	95-104